Figure 1
Figure 1. Ibrutinib but not acalabrutinib treatment of CLL patients increases total T cell numbers: (A) Absolute numbers of CD8 T cells before and during ibrutinib treatment (n=18). (B) Absolute numbers of CD8 T cells before and during acalabrutinib treatment (n=8). Each cycle is 4 weeks. "Cycle 3" day 1 indicates 8 weeks into treatment, and "cycle 6" day 1 indicates 20 weeks into treatment.

Ibrutinib but not acalabrutinib treatment of CLL patients increases total T cell numbers: (A) Absolute numbers of CD8 T cells before and during ibrutinib treatment (n=18). (B) Absolute numbers of CD8 T cells before and during acalabrutinib treatment (n=8). Each cycle is 4 weeks. "Cycle 3" day 1 indicates 8 weeks into treatment, and "cycle 6" day 1 indicates 20 weeks into treatment.

Close Modal

or Create an Account

Close Modal
Close Modal